Analysis and research on adverse drug reactions of anti-tumor drugs based on pharmacovigilance and risk control system in Guangdong Province
Objective To analyze the general situation,characteristics and rules of adverse drug reaction(ADR)reports of anti-tumor drugs,and to study the influencing factors of ADR.Methods The adverse reactions of anti-tumor drugs in Jiangmen City from 2020 to 2021 were collected and analyzed retrospectively through the pharmacovigilance and risk control system of Guangdong Province.Results The serious ADR reports of anti-tumor drugs in 2020 and 2021 accounted for about 40%of the city's serious ADR reports.Compared with traditional anti-tumor drugs,the proportion of women is higher than that of men,and the proportion of men and women in new anti-tumor drugs is more balanced.The top three routes of administration of traditional anti-tumor drugs and new anti-tumor drugs in the ADR reports of 2020 and 2021 were consistent,mainly intravenous administration.The top three traditional anti-tumor drugs were paclitaxel,docetaxel and oxaliplatin,and the top three new anti-tumor drugs were trastuzumab injection,sintilizumab injection and bevacizumab injection.Conclusion It is necessary to continuously strengthen the monitoring of adverse reactions of anti-tumor drugs,pay attention to the groups prone to ADR,and adopt pharmaceutical care measures to reduce the occurrence of ADR.Effective measures should be taken as soon as possible to improve the safety of patients.
Pharmacovigilance and risk control system in Guangdong ProvinceAnti-tumor drugAdverse drug reactionMedication safety
万方数据
维普
